Carmen Clapp Selected Research

Prolactin

1/2022	Dual Roles of Prolactin and Vasoinhibin in Inflammatory Arthritis.
1/2021	Global Deletion of the Prolactin Receptor Aggravates Streptozotocin-Induced Diabetes in Mice.
11/2020	Prolactin stimulates the vascularisation of the retina in newborn mice under hyperoxia conditions.
1/2020	Levosulpiride Increases the Levels of Prolactin and Antiangiogenic Vasoinhibin in the Vitreous of Patients with Proliferative Diabetic Retinopathy.
1/2020	Vasoinhibin reduces joint inflammation, bone loss, and the angiogenesis and vasopermeability of the pannus in murine antigen-induced arthritis.
1/2020	Low prolactin levels are associated with visceral adipocyte hypertrophy and insulin resistance in humans.
1/2019	A Dysregulation of the Prolactin/Vasoinhibin Axis Appears to Contribute to Preeclampsia.
1/2018	Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema.
1/2017	Human Prolactin Point Mutations and Their Projected Effect on Vasoinhibin Generation and Vasoinhibin-Related Diseases.
1/2017	Remarks on the Prolactin Hypothesis of Peripartum Cardiomyopathy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carmen Clapp Research Topics

Disease

10	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2022 - 06/2008
10	Hyperprolactinemia 01/2022 - 12/2010
7	Inflammation (Inflammations) 01/2022 - 09/2013
6	Arthritis (Polyarthritis) 01/2022 - 09/2013
5	Cardiomyopathies (Cardiomyopathy) 01/2017 - 11/2007
4	Neoplasms (Cancer) 01/2022 - 11/2003
4	Type 2 Diabetes Mellitus (MODY) 01/2020 - 05/2015
4	Retinopathy of Prematurity (Retrolental Fibroplasia) 01/2017 - 07/2004
3	Pre-Eclampsia (Preeclampsia) 04/2022 - 01/2017
3	Obesity 01/2021 - 01/2017
3	Insulin Resistance 01/2020 - 05/2015
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020 - 05/2015
3	Macular Edema 01/2018 - 03/2016
3	Blindness (Hysterical Blindness) 05/2016 - 06/2008
3	Ganglion Cysts (Ganglion) 02/2008 - 08/2005
2	Glucose Intolerance 01/2021 - 01/2020
2	Hypoxia (Hypoxemia) 01/2020 - 11/2003
2	Hypertrophy 01/2020 - 01/2017
2	Retinal Degeneration 11/2019 - 01/2014
2	Birth Weight (Birth Weights) 01/2017 - 10/2007
2	Diabetes Mellitus 01/2015 - 10/2011
1	COVID-19 01/2022
1	Melanoma (Melanoma, Malignant) 01/2022
1	Hyperglycemia 01/2021
1	Gestational Diabetes (Gestational Diabetes Mellitus) 01/2021
1	Hyperoxia 11/2020
1	Prolactinoma (Prolactinomas) 01/2020
1	Osteitis 01/2020
1	Hyperplasia 01/2020
1	Rupture 11/2019
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 09/2019
1	Pheochromocytoma 01/2019
1	Ischemia 01/2018
1	Disease Progression 01/2018
1	Pulmonary Edema 10/2017
1	Pregnancy-Induced Hypertension (Hypertension, Pregnancy Induced) 01/2017
1	Sepsis (Septicemia) 01/2017
1	Rheumatoid Arthritis 01/2016
1	Heart Diseases (Heart Disease) 11/2015
1	Metabolic Diseases (Metabolic Disease) 05/2015
1	Rheumatic Diseases (Rheumatism) 07/2014
1	Phototoxic Dermatitis (Phototoxicity) 01/2014
1	Gliosis 01/2014
1	Anxiety Disorders (Anxiety Disorder) 11/2013
1	Body Weight (Weight, Body) 10/2013
1	Pain (Aches) 09/2013
1	Cataract (Cataracts) 09/2010

Drug/Important Bio-Agent (IBA)

27	ProlactinIBA 01/2022 - 11/2003
16	Retinaldehyde (Retinal)IBA 01/2022 - 09/2007
13	Hormones (Hormone)IBA 01/2022 - 01/2006
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 11/2003
6	CytokinesIBA 01/2020 - 09/2013
4	levosulpirideIBA 01/2022 - 01/2017
2	Placental Lactogen (Human Placental Lactogen)IBA 04/2022 - 01/2019
2	AntigensIBA 01/2022 - 01/2020
2	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2020
2	Prolactin Receptors (Prolactin Receptor)IBA 01/2021 - 01/2014
2	Cathepsin DIBA 11/2020 - 11/2003
2	Angiogenesis InhibitorsIBA 01/2018 - 11/2003
2	Peptides (Polypeptides)IBA 11/2013 - 10/2007
2	Capsules (Microcapsules)IBA 10/2013 - 12/2010
2	Messenger RNA (mRNA)IBA 08/2005 - 11/2003
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	IntegrinsIBA 01/2022
1	Dopamine D2 Receptor AntagonistsIBA 01/2022
1	Sulpiride (neogama)IBA 01/2022
1	Streptozocin (Streptozotocin)FDA Link 01/2021
1	Insulin (Novolin)FDA Link 01/2021
1	Peptide Hydrolases (Proteases)FDA Link 11/2020
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2020
1	Blood Glucose (Blood Sugar)IBA 01/2020
1	HDL LipoproteinsIBA 01/2020
1	Triglycerides (Triacylglycerol)IBA 01/2020
1	Platelet Endothelial Cell Adhesion Molecule-1IBA 01/2020
1	Sarcoglycans (beta Sarcoglycan)IBA 11/2019
1	Purinergic P2X7 ReceptorsIBA 09/2019
1	Nerve Growth Factor (NGF)IBA 01/2019
1	Peptide Hormones (Polypeptide Hormones)IBA 01/2019
1	EnzymesIBA 01/2019
1	Ranibizumab (Lucentis)FDA Link 01/2018
1	CalciumIBA 10/2017
1	LigandsIBA 01/2017
1	Dopamine (Intropin)FDA LinkGeneric 01/2017
1	Bromocriptine (Parlodel)FDA LinkGeneric 01/2017
1	Dopamine Agonists (Dopamine Agonist)IBA 11/2016
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2015
1	Transforming Growth Factors (Transforming Growth Factor)IBA 05/2015
1	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 01/2014
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2014
1	Nerve Growth Factors (Neurotrophins)IBA 01/2014
1	Interleukin-6 (Interleukin 6)IBA 10/2013
1	Pituitary HormonesIBA 10/2011
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 10/2008
1	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 10/2008
1	Phosphoprotein Phosphatases (Phosphatases, Protein)IBA 06/2008

Therapy/Procedure

5	Therapeutics 01/2018 - 12/2010
3	Vitrectomy 01/2020 - 09/2010
2	Intra-Articular Injections 01/2022 - 01/2020
1	Oral Administration 01/2022
1	Phacoemulsification 09/2010